Diagnostics and Prognostics of Prostate Cancer

The Need: Addressing Prostate Cancer Diagnostics and Therapeutics

Prostate cancer remains a significant challenge in medical diagnosis and treatment, requiring advancements in diagnostics, therapeutics, and prognostics. Current approaches fall short in providing accurate and effective solutions, leading to a need for innovative technologies that can revolutionize the field of prostate-related disorders.

The Technology: MicroRNA-based Biomarker Detection

Our cutting-edge technology is based on the identification and measurement of specific microRNA (miRNA) biomarkers associated with prostate cancer. miRNAs play a crucial role in regulating gene expression, and their expression profiles have been linked to various cancer types, including prostate cancer. We have developed a sophisticated method to diagnose, prognose, and treat prostate-related disorders by quantifying the levels of miRNA biomarkers in patient samples.

Commercial Applications:

  1. Diagnostics: Accurate and early diagnosis of prostate cancer through miRNA biomarker profiling in blood or tissue samples.
  2. Therapeutics: Development of targeted therapies by modulating miRNA expression to inhibit cancer cell growth and metastasis.
  3. Prognostics: Predicting disease progression and patient outcomes based on miRNA expression patterns.
  4. Patient Stratification: Identifying patients who are likely to respond favorably to specific treatments based on their miRNA profiles.
  5. Research Tools: Providing researchers with valuable tools to study prostate cancer biology and develop novel treatment strategies.


  1. Precision Diagnostics: Our technology enables precise and early detection of prostate cancer, improving patient outcomes and survival rates.
  2. Personalized Therapeutics: Tailoring treatment plans based on individual miRNA profiles leads to more effective and targeted therapies, reducing side effects.
  3. Enhanced Prognosis: Accurate prediction of disease progression helps clinicians make informed decisions about treatment strategies.
  4. Cost-Effectiveness: Our technology streamlines diagnostic processes, reducing the need for expensive and invasive procedures.
  5. Research Advancements: Researchers can leverage our miRNA profiling tools to gain insights into prostate cancer biology, facilitating the development of novel therapeutic approaches.

Contact us today to learn more about how our miRNA-based technology can revolutionize prostate cancer diagnostics and therapeutics. Together, we can make a significant impact in the fight against prostate-related disorders.


Patent # Title Country
EP2799557 MiR-32 Antagonists for Increasing Responsiveness of Prostate Cancer to Apoptosis Italy

Loading icon